This report provides information on the therapeutic development for Neisseriaceae Infections, complete with latest updates, and special features on late-stage and discontinued projects.

1. Neisseriaceae Infections - Pipeline Review, Q3 2011
Summary
Global Markets Direct’s, 'Neisseriaceae Infections - Pipeline Review, Q3 2011',
provides an overview of the Neisseriaceae Infections therapeutic pipeline. This
report provides information on the therapeutic development for Neisseriaceae
Infections, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic
development for Neisseriaceae Infections. 'Neisseriaceae Infections - Pipeline
Review, Q3 2011' is built using data and information sourced from Global Markets
Direct’s proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Neisseriaceae Infections.
- A review of the Neisseriaceae Infections products under development by
companies and universities/research institutes based on information derived from
company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
- Coverage of the Neisseriaceae Infections pipeline on the basis of therapeutic
class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description,
mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Browse All Pharmaceuticals Market Research Reports
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Neisseriaceae Infections.
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most
promising pipeline.
- Devise corrective measures for pipeline projects by understanding Neisseriaceae

2. Infections pipeline depth and focus of Neisseriaceae Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and
understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neisseriaceae Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Neisseriaceae Infections 7
Neisseriaceae Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Neisseriaceae Infections Therapeutics - Products under Development by Companies
13
Companies Involved in Neisseriaceae Infections Therapeutics Development 14
GlaxoSmithKline plc 14
Kenta Biotech Ltd. 14
Endo Pharmaceuticals Inc. 15
Neisseriaceae Infections - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
PRO 2000/5 Gel - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
KBAB401 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Heptavalent Combination Vaccine - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23

3. Hexavalent Combination Vaccine - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Neisseriaceae Infections Therapeutics – Drug Profile Updates 25
Neisseriaceae Infections - Featured News 26
Sep 12, 2010: Novartis Phase III Study Shows Meningococcal B Vaccine Candidate
Could Be First To Provide Broad Coverage Against Deadly Disease 26
Sep 12, 2010: Novartis Presents Phase III Study Results On Multicomponent
Meningococcal Serogroup B Vaccine At International Pathogenic Neisseria
Conference 27
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 30
Contact Us 30
Disclaimer 30
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and
in-depth market research studies & analysis of over 5000 micro markets. We
provide 24/7 online and offline support to our customers. Get in touch with us for
your needs of market research reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page:
http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: +1-888-989-8004
E-mail: sales@reportsandreports.com
http://www.reportsandreports.com
Visit our Market Research Blog